EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma

Tallys Feldens iD, Roselene Mesquita Augusto Passos iD, Juliana de Oliveira Martins, Alessandro Gonçalves Campolina iD, Cesar de Almeida Neto iD

Expert Review of Pharmacoeconomics & Outcomes Research · 2026

DOI: 10.1080/14737167.2026.2612985 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2026. Verfasst von Tallys Feldens und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department L'EMbeDS, Institute of Management, Sant'Anna School for Advanced Studies, Pisa, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Mobilization, Heterocyclic Compounds, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Multiple myeloma (MM) is a hematologic cancer with rising incidence worldwide. Autologous stem cell transplantation (ASCT) is a key treatment for eligible patients, but mobilization failure remains a major obstacle. Plerixafor enhances stem cell mobilization, but its high costs and lack of standardized protocol prevent its widespread use. OBJECTIVE: To evaluate the cost-utility of preemptive versus rescue use of plerixafor for hematopoietic stem cell mobilization inMM patients. METHODS: A Markov model was developed using real-world data from 196 MM patients undergoing stem cell mobilization at two SãoPaulo transplant centers in Brazil. The model compared two strategies: (1) preemptive plerixafor and (2) rescue plerixafor use following mobilization failure. Transition probabilities, utilities, and costs were informed by clinical data and literature. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: The preemptive strategy led to higher rates of successful mobilization and ASCT, resulting in greater quality-adjusted life years (QALYs), but also higher costs. Still, it demonstrated favorable results compared to the rescue approach and passed the Brazilian willingness to pay thresholds of acceptability. CONCLUSION: Preemptive plerixafor passes the cost-utility guidelines to be used in MM patients in Brazil, potentially guiding policy decisions on resource allocation within the national health system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell MobilizationHeterocyclic CompoundsHematopoietic Stem Cell TransplantationHumansCyclamsBenzylaminesCost-Benefit AnalysisMarkov ChainsBrazilQuality-Adjusted Life YearsTransplantation, AutologousMiddle AgedFemale

Stichwörter der Autor:innen

ASCTCost-utilitymarkovmultiple myelomaplerixafor

Substanzen

plerixaforCyclamsBenzylaminesHeterocyclic Compounds

Autor:innen und Institutionen

  • Department L'EMbeDS, Institute of Management, Sant'Anna School for Advanced Studies, Pisa, Italy.
  • NEIDE (International Economics and Economic Development Research Group), Federal University of Parana, Curitiba, Brazil.
  • RISE, Centre for Health Technology and Services Research, Porto, Portugal.
  • Bone Marrow Transplant Unit, Hospital de Transplantes Euryclides de Jesus Zerbini, Sao Paulo, Brazil.
  • Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil.
  • Departamento de Aféreses, Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.

ORCID-Profile: Tallys Feldens, Roselene Mesquita Augusto Passos, Alessandro Gonçalves Campolina, Cesar de Almeida Neto

Zitieren

APA

Feldens, T., Mesquita Augusto Passos, R., de Oliveira Martins, J., Campolina, A. G., & de Almeida Neto, C. (2026). Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2026.2612985

Vancouver

Feldens T, Mesquita Augusto Passos R, de Oliveira Martins J, Campolina AG, de Almeida Neto C. Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research. 2026. doi:10.1080/14737167.2026.2612985

BibTeX
@article{Feldens2026,
  author = {Feldens, Tallys and Mesquita Augusto Passos, Roselene and de Oliveira Martins, Juliana and Campolina, Alessandro Gonçalves and de Almeida Neto, Cesar},
  title = {Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  doi = {10.1080/14737167.2026.2612985}
}
Kostenlos starten →